Clinical Applications and What Comes Next
The FDA has now approved two live biotherapeutic products for recurrent C. difficile — a milestone that establishes the regulatory pathway for microbiome-based medicines. Several companies are advancing precision microbiome therapies through Phase 2 and 3 trials for conditions from graft-versus-host disease to nonalcoholic steatohepatitis.
Oncology may be where microbiome research has its most immediate clinical impact. Antibiotics taken near the time of cancer diagnosis or immunotherapy treatment negatively affect outcomes in multiple studies, likely by disrupting the microbial ecosystem that supports immune responses. Oncologists are increasingly asking about antibiotic use when patients fail to respond to otherwise effective treatments.
KEY TAKEAWAYS
- Gut microbiome diversity predicts metabolic health better than BMI alone
- Fermented foods significantly increase microbiome diversity in randomized trials
- Microbiome composition predicts cancer immunotherapy response
- FMT trials are underway for obesity, autism, and Parkinson’s disease
- Next-generation precision probiotics target specific therapeutic mechanisms
- Consumer microbiome testing currently has limited clinical utility